Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. (Q37279990)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18819158%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18819158%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Richard Pietras

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18819158%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Sara A Hurvitz

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18819158%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

language of work or name

0 references

publication date

1 November 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18819158%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18819158%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

113

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18819158%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18819158%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

2385-2397

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18819158%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Oophorectomy for breast cancer: history revisited.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

21 January 2018

Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

21 January 2018

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

21 January 2018

Paradoxical Action of Fulvestrant in Estradiol-Induced Regression of Tamoxifen-Stimulated Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

21 January 2018

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole in the neoadjuvant setting: the P024 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Life following aromatase inhibitors--where now for endocrine sequencing?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Membrane-associated estrogen receptor signaling pathways in human cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Signaling regulation of genomic and nongenomic functions of estrogen receptors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Production and actions of estrogens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Oestrogen receptors - an overview

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

The protective effects of estrogen on the cardiovascular system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired tamoxifen resistance in human breast cancer--potential mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

CYP2D6 polymorphisms and the impact on tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

What clinicians need to know about antioestrogen resistance in breast cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

New approaches to reverse resistance to hormonal therapy in human breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

New approaches to the understanding of tamoxifen action and resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term exposure to tamoxifen induces hypersensitivity to estradiol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine therapy--current benefits and limitations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of tamoxifen resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Biological effects of progestins in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine therapy for advanced breast cancer: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23875

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37279990&oldid=1966926058"